Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

New math model sheds light on multiple sclerosis relapse and recovery cycles

A new mathematical model that reproduces the relapsing-remitting pattern of multiple sclerosis (MS) offers scientists a tool to better understand how the disease progresses. The model, developed by QUT researchers from the School of Mathematical Sciences, is published in the Journal of the Royal Society Interface.

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of

FDA OKs first clinical trial testing novel oral therapy in MS patients

Following the submission of thousands of pages of documentation, the U.S. Food and Drug Administration (FDA) has given the green light for a mid-stage clinical trial of Lucid-MS, a potential first-in-class oral therapy for multiple sclerosis  (MS). With the FDA’s clearance of an investigational new drug (IND) application from developer Quantum Biopharma, the therapy candidate […] The post FDA OKs first clinical trial testing novel oral therapy i…

Quantum BioPharma Gets FDA Green Light for Lucid-MS Phase 2 Trial in Multiple Sclerosis

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), allowing the company to advance this first-in-class multiple sclerosis (MS) candidate into Phase 2 clinical development. The approval, disclosed on August 10, 2026, paves the way for a randomized, double-blind, placebo-controlled study designed to eval…